SE0100903D0 - Compounds - Google Patents

Compounds

Info

Publication number
SE0100903D0
SE0100903D0 SE0100903A SE0100903A SE0100903D0 SE 0100903 D0 SE0100903 D0 SE 0100903D0 SE 0100903 A SE0100903 A SE 0100903A SE 0100903 A SE0100903 A SE 0100903A SE 0100903 D0 SE0100903 D0 SE 0100903D0
Authority
SE
Sweden
Prior art keywords
compounds
inhibitors
mmp12
useful
formula
Prior art date
Application number
SE0100903A
Other languages
English (en)
Swedish (sv)
Inventor
Matti Lepistoe
Af Rosenschoeld Magnus Munck
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0100903A priority Critical patent/SE0100903D0/xx
Publication of SE0100903D0 publication Critical patent/SE0100903D0/xx
Priority to BR0207985-2A priority patent/BR0207985A/pt
Priority to PCT/SE2002/000479 priority patent/WO2002074752A1/en
Priority to CNB028097890A priority patent/CN1313448C/zh
Priority to MXPA03008180A priority patent/MXPA03008180A/es
Priority to BR0208062-1A priority patent/BR0208062A/pt
Priority to CZ20032498A priority patent/CZ20032498A3/cs
Priority to JP2002573761A priority patent/JP2004527512A/ja
Priority to SK1093-2003A priority patent/SK10932003A3/sk
Priority to RU2003127731/04A priority patent/RU2003127731A/ru
Priority to PCT/SE2002/000475 priority patent/WO2002074750A1/en
Priority to MXPA03008187A priority patent/MXPA03008187A/es
Priority to KR1020037011980A priority patent/KR100865836B1/ko
Priority to EEP200300452A priority patent/EE200300452A/xx
Priority to JP2002573758A priority patent/JP2004523582A/ja
Priority to RU2003127732/04A priority patent/RU2003127732A/ru
Priority to US10/471,808 priority patent/US20040147573A1/en
Priority to RU2003127736/04A priority patent/RU2293730C2/ru
Priority to PL02364714A priority patent/PL364714A1/xx
Priority to UA2003098169A priority patent/UA74624C2/uk
Priority to SK1094-2003A priority patent/SK10942003A3/sk
Priority to NZ528141A priority patent/NZ528141A/en
Priority to JP2002573759A priority patent/JP2004527511A/ja
Priority to UA2003098167A priority patent/UA77169C2/uk
Priority to CA002440632A priority patent/CA2440632A1/en
Priority to EP02704034A priority patent/EP1370536A1/en
Priority to HU0400328A priority patent/HUP0400328A3/hu
Priority to MYPI20020912A priority patent/MY129188A/en
Priority to KR10-2003-7011989A priority patent/KR20030082990A/ko
Priority to US10/471,499 priority patent/US20040110809A1/en
Priority to CNA028100417A priority patent/CN1509275A/zh
Priority to CNA028099273A priority patent/CN1509274A/zh
Priority to IL15765002A priority patent/IL157650A0/xx
Priority to BR0208105-9A priority patent/BR0208105A/pt
Priority to EP02704033A priority patent/EP1370535A1/en
Priority to NZ528108A priority patent/NZ528108A/en
Priority to EP02704038A priority patent/EP1370538A1/en
Priority to HU0400193A priority patent/HUP0400193A3/hu
Priority to AU2002237633A priority patent/AU2002237633B2/en
Priority to EEP200300450A priority patent/EE200300450A/xx
Priority to IL15765802A priority patent/IL157658A0/xx
Priority to SK1091-2003A priority patent/SK10912003A3/sk
Priority to CA002440475A priority patent/CA2440475A1/en
Priority to EEP200300439A priority patent/EE200300439A/xx
Priority to HU0400206A priority patent/HUP0400206A3/hu
Priority to US10/471,501 priority patent/US20040116486A1/en
Priority to CZ20032501A priority patent/CZ20032501A3/cs
Priority to MXPA03008183A priority patent/MXPA03008183A/es
Priority to CZ20032502A priority patent/CZ20032502A3/cs
Priority to PL02364705A priority patent/PL364705A1/xx
Priority to PL02365107A priority patent/PL365107A1/xx
Priority to PCT/SE2002/000474 priority patent/WO2002074749A1/en
Priority to IL15757002A priority patent/IL157570A0/xx
Priority to CA002444526A priority patent/CA2444526A1/en
Priority to KR10-2003-7011983A priority patent/KR20030082988A/ko
Priority to ARP020100945A priority patent/AR035444A1/es
Priority to ZA200306733A priority patent/ZA200306733B/en
Priority to ZA200306738A priority patent/ZA200306738B/en
Priority to IS6945A priority patent/IS6945A/is
Priority to IS6944A priority patent/IS6944A/is
Priority to NO20034025A priority patent/NO20034025L/no
Priority to IS6948A priority patent/IS6948A/is
Priority to NO20034032A priority patent/NO20034032L/no
Priority to NO20034027A priority patent/NO326088B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
SE0100903A 2001-03-15 2001-03-15 Compounds SE0100903D0 (sv)

Priority Applications (64)

Application Number Priority Date Filing Date Title
SE0100903A SE0100903D0 (sv) 2001-03-15 2001-03-15 Compounds
BR0207985-2A BR0207985A (pt) 2001-03-15 2002-03-13 Inibidores de metaloproteinase
PCT/SE2002/000479 WO2002074752A1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
CNB028097890A CN1313448C (zh) 2001-03-15 2002-03-13 金属蛋白酶抑制剂
MXPA03008180A MXPA03008180A (es) 2001-03-15 2002-03-13 Inhibidores de metaloproteinasa.
BR0208062-1A BR0208062A (pt) 2001-03-15 2002-03-13 Inibidores de metaloproteinase
CZ20032498A CZ20032498A3 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
JP2002573761A JP2004527512A (ja) 2001-03-15 2002-03-13 メタロプロテイナーゼ阻害剤
SK1093-2003A SK10932003A3 (sk) 2001-03-15 2002-03-13 Metaloproteinázové inhibítory
RU2003127731/04A RU2003127731A (ru) 2001-03-15 2002-03-13 Ингибиторы металлопротеиназ
PCT/SE2002/000475 WO2002074750A1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
MXPA03008187A MXPA03008187A (es) 2001-03-15 2002-03-13 Inhibidores de metaloproteinasas.
KR1020037011980A KR100865836B1 (ko) 2001-03-15 2002-03-13 메탈로프로테이나제 억제제
EEP200300452A EE200300452A (et) 2001-03-15 2002-03-13 Metalloproteinaasi inhibiitorid
JP2002573758A JP2004523582A (ja) 2001-03-15 2002-03-13 メタロプロテイナーゼ阻害剤
RU2003127732/04A RU2003127732A (ru) 2001-03-15 2002-03-13 Ингибиторы металлопротеиназ
US10/471,808 US20040147573A1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
RU2003127736/04A RU2293730C2 (ru) 2001-03-15 2002-03-13 Ингибиторы металлопротеиназ, их применение и фармацевтические композиции на их основе
PL02364714A PL364714A1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
UA2003098169A UA74624C2 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
SK1094-2003A SK10942003A3 (sk) 2001-03-15 2002-03-13 Metaloproteinázové inhibítory
NZ528141A NZ528141A (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
JP2002573759A JP2004527511A (ja) 2001-03-15 2002-03-13 メタロプロテイナーゼ阻害剤
UA2003098167A UA77169C2 (en) 2001-03-15 2002-03-13 Hidantoine derivatives, pharmaceutical composition, their use
CA002440632A CA2440632A1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
EP02704034A EP1370536A1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
HU0400328A HUP0400328A3 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitor azoles and pharmaceutical compositions containing them
MYPI20020912A MY129188A (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
KR10-2003-7011989A KR20030082990A (ko) 2001-03-15 2002-03-13 메탈로프로테이나제 억제제
US10/471,499 US20040110809A1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
CNA028100417A CN1509275A (zh) 2001-03-15 2002-03-13 金属蛋白酶抑制剂
CNA028099273A CN1509274A (zh) 2001-03-15 2002-03-13 金属蛋白酶抑制剂
IL15765002A IL157650A0 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
BR0208105-9A BR0208105A (pt) 2001-03-15 2002-03-13 Inibidores de metaloproteinase
EP02704033A EP1370535A1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
NZ528108A NZ528108A (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
EP02704038A EP1370538A1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
HU0400193A HUP0400193A3 (en) 2001-03-15 2002-03-13 Imidazolindion derivatives as metalloproteinase inhibitors, their use and pharmaceutical compositions containing them
AU2002237633A AU2002237633B2 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
EEP200300450A EE200300450A (et) 2001-03-15 2002-03-13 Metalloproteinaasi inhibiitorid
IL15765802A IL157658A0 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
SK1091-2003A SK10912003A3 (sk) 2001-03-15 2002-03-13 Metaloproteinázové inhibítory
CA002440475A CA2440475A1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
EEP200300439A EE200300439A (et) 2001-03-15 2002-03-13 Metalloproteinaasi inhibiitorid
HU0400206A HUP0400206A3 (en) 2001-03-15 2002-03-13 Imidazolidindion derivatives having metalloproteinase inhibitor effect a their use for preparation of pharmaceutical compositions and pharmaceutical compositions containing them
US10/471,501 US20040116486A1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
CZ20032501A CZ20032501A3 (cs) 2001-03-15 2002-03-13 Inhibitory metaloproteinasy
MXPA03008183A MXPA03008183A (es) 2001-03-15 2002-03-13 Inhibidores de metaloproteinasa.
CZ20032502A CZ20032502A3 (cs) 2001-03-15 2002-03-13 Inhibitory metalloproteinasy
PL02364705A PL364705A1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
PL02365107A PL365107A1 (en) 2001-03-15 2002-03-13 Compounds
PCT/SE2002/000474 WO2002074749A1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
IL15757002A IL157570A0 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
CA002444526A CA2444526A1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors
KR10-2003-7011983A KR20030082988A (ko) 2001-03-15 2002-03-13 메탈로프로테이나제 억제제
ARP020100945A AR035444A1 (es) 2001-03-15 2002-03-15 Compuestos inhibidores de metaloproteinasas, composicion farmaceutica, metodo de tratamiento, y uso de estos compuestos para la preparacion de medicamentos
ZA200306733A ZA200306733B (en) 2001-03-15 2003-08-28 Metalloproteinase inhibitors.
ZA200306738A ZA200306738B (en) 2001-03-15 2003-08-28 Metalloproteinase inhibitors.
IS6945A IS6945A (is) 2001-03-15 2003-09-10 Málmpróteinasatálmar
IS6944A IS6944A (is) 2001-03-15 2003-09-10 Málmpróteinasatálmar
NO20034025A NO20034025L (no) 2001-03-15 2003-09-11 Metalloproteinaseinhibitorer
IS6948A IS6948A (is) 2001-03-15 2003-09-11 M βlmproteinasat βlmar
NO20034032A NO20034032L (no) 2001-03-15 2003-09-11 Metallproteinase-inhibitorer
NO20034027A NO326088B1 (no) 2001-03-15 2003-09-11 Metalloproteinaseinhibitorer, farmasoytiske sammensetninger inneholdende slike samt anvendelser derav

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0100903A SE0100903D0 (sv) 2001-03-15 2001-03-15 Compounds

Publications (1)

Publication Number Publication Date
SE0100903D0 true SE0100903D0 (sv) 2001-03-15

Family

ID=20283375

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0100903A SE0100903D0 (sv) 2001-03-15 2001-03-15 Compounds

Country Status (25)

Country Link
US (2) US20040110809A1 (cs)
EP (2) EP1370535A1 (cs)
JP (2) JP2004523582A (cs)
KR (2) KR100865836B1 (cs)
CN (2) CN1313448C (cs)
AR (1) AR035444A1 (cs)
AU (1) AU2002237633B2 (cs)
BR (2) BR0207985A (cs)
CA (2) CA2440475A1 (cs)
CZ (2) CZ20032501A3 (cs)
EE (2) EE200300450A (cs)
HU (2) HUP0400193A3 (cs)
IL (2) IL157650A0 (cs)
IS (2) IS6945A (cs)
MX (2) MXPA03008187A (cs)
MY (1) MY129188A (cs)
NO (2) NO326088B1 (cs)
NZ (2) NZ528141A (cs)
PL (2) PL365107A1 (cs)
RU (2) RU2293730C2 (cs)
SE (1) SE0100903D0 (cs)
SK (2) SK10912003A3 (cs)
UA (2) UA77169C2 (cs)
WO (2) WO2002074752A1 (cs)
ZA (2) ZA200306733B (cs)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5300399A1 (es) 2000-02-25 2003-07-31 Astrazeneca Ab Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen
US7005439B2 (en) * 2000-06-20 2006-02-28 Astrazeneca Ab Compounds
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
CA2447475A1 (en) 2001-05-25 2002-12-05 Chu-Biao Xue Hydantion derivatives as inhibitors of matrix metalloproteinases
SE0103710D0 (sv) 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
MY131170A (en) * 2002-03-28 2007-07-31 Nissan Chemical Ind Ltd Therapeutic agent for glomerular disease
SE0202539D0 (sv) * 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
SE0202692D0 (sv) * 2002-09-11 2002-09-11 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
FR2845000B1 (fr) * 2002-09-27 2005-05-27 Oreal Utilisation d'un compose heterocyclique ou de l'un de ses sels pour stimuler ou induire la pousse des cheveux et/ou freiner leur chute
SE0401763D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Compounds
SE0401762D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
DK1789036T3 (da) * 2004-08-19 2011-06-27 Quest Pharmaceutical Services 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2,4-dion og analoger som inhibitorer af makrofagelastase
JPWO2006051937A1 (ja) * 2004-11-15 2008-05-29 塩野義製薬株式会社 ヘテロ５員環誘導体
SE0403085D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
SE0403086D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
TW200740769A (en) * 2006-03-16 2007-11-01 Astrazeneca Ab Novel process
CN103435595A (zh) 2006-05-08 2013-12-11 阿里亚德医药股份有限公司 炔类杂芳基化合物
US8278307B2 (en) 2006-05-08 2012-10-02 Ariad Pharmaceuticals, Inc. Monocyclic Heteroaryl compounds
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
ES2313841B1 (es) * 2007-06-26 2010-01-12 Proyecto De Biomedicina Cima, S.L. Composiciones para tratamiento anti-fibrinolitico.
CA2743449C (en) 2008-11-12 2016-10-18 Ariad Pharmaceuticals, Inc. Pyrazinopyrazines and derivatives as kinase inhibitors
US8492556B2 (en) * 2011-11-10 2013-07-23 Allergan, Inc. 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators
EP2907512A1 (en) 2014-02-14 2015-08-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Inhibitors of MMP-12 as antiviral Agents
KR102314286B1 (ko) * 2016-12-16 2021-10-21 화이자 인코포레이티드 Glp-1 수용체 작용제 및 이의 용도
KR102861502B1 (ko) 2018-05-15 2025-09-18 포시 파마슈티컬스 유에스에이 인코포레이티드 기질 금속단백분해효소 (mmp) 억제제 및 이의 사용 방법

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2745875A (en) * 1953-06-30 1956-05-15 Hoechst Ag Preparation of nu-acylamino-phenylpropane diols
US3452040A (en) * 1966-01-05 1969-06-24 American Home Prod 5,5-disubstituted hydantoins
US3529019A (en) * 1968-04-23 1970-09-15 Colgate Palmolive Co Alkylaryloxy alanines
US3849574A (en) * 1971-05-24 1974-11-19 Colgate Palmolive Co Alpha-substituted-beta-arylthioalkyl amino-acids,for increasing heart rate
US4315031A (en) * 1977-09-01 1982-02-09 Science Union Et Cie Thiosubstituted amino acids
GB1601310A (en) * 1978-05-23 1981-10-28 Lilly Industries Ltd Aryl hydantoins
JPS61212292A (ja) * 1985-03-19 1986-09-20 Mitsui Toatsu Chem Inc Ｄ−α−アミノ酸の製造方法
JPH0597814A (ja) * 1991-10-02 1993-04-20 Ajinomoto Co Inc ５−（ヒドロキシメチル）ヒダントイン誘導体の製法
PH31245A (en) * 1991-10-30 1998-06-18 Janssen Pharmaceutica Nv 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives.
US5308853A (en) * 1991-12-20 1994-05-03 Warner-Lambert Company Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties
US5246943A (en) * 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
EP0640594A1 (en) * 1993-08-23 1995-03-01 Fujirebio Inc. Hydantoin derivative as metalloprotease inhibitor
US6166041A (en) * 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
DE19540027A1 (de) * 1995-10-27 1997-04-30 Gruenenthal Gmbh Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe
IL123431A (en) * 1995-11-22 2001-05-20 Darwin Discovery Ltd Mercaptoalkyl peptidil compounds with imidazole transducer and their use as metallic protonase matrix (MMP) compounds and / or tumor cause factor (TNF)
GB9616643D0 (en) * 1996-08-08 1996-09-25 Chiroscience Ltd Compounds
US5919790A (en) * 1996-10-11 1999-07-06 Warner-Lambert Company Hydroxamate inhibitors of interleukin-1β converting enzyme
WO1998017645A1 (en) * 1996-10-22 1998-04-30 Pharmacia & Upjohn Company α-AMINO SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS
WO1998050359A1 (en) * 1997-05-06 1998-11-12 Novo Nordisk A/S Novel heterocyclic compounds
PT877019E (pt) * 1997-05-09 2002-05-31 Hoechst Ag Acidos diaminocarboxilicos substituidos
PL337854A1 (en) * 1997-07-31 2000-09-11 Abbott Lab Inverse hydroxamines as inhibitors of intercellular substance metaloproteinases
JP4750272B2 (ja) * 1998-02-04 2011-08-17 ノバルティス アーゲー マトリックス分解メタロプロテイナーゼを阻害するスルホニルアミノ誘導体
US6329418B1 (en) * 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
AU4074799A (en) * 1998-05-14 1999-11-29 Du Pont Pharmaceuticals Company Substituted aryl hydroxamic acids as metalloproteinase inhibitors
CA2333554A1 (en) * 1998-06-17 1999-12-23 Chu-Baio Xue Cyclic hydroxamic acids as metalloproteinase inhibitors
US6339101B1 (en) * 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
EP1004578B1 (en) * 1998-11-05 2004-02-25 Pfizer Products Inc. 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
AU1817700A (en) * 1998-12-31 2000-07-24 Aventis Pharmaceuticals Inc. 1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12
US6340691B1 (en) * 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
US20020006920A1 (en) * 1999-07-22 2002-01-17 Robinson Ralph Pelton Arylsulfonylamino hydroxamic acid derivatives
ES2258431T3 (es) * 1999-08-02 2006-09-01 F. Hoffmann-La Roche Ag Proceso para la preparacion de derivados de benzotiofeno.
WO2001012189A1 (en) * 1999-08-12 2001-02-22 Pharmacia Italia S.P.A. 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
US6525202B2 (en) * 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US20020065219A1 (en) * 2000-08-15 2002-05-30 Naidu B. Narasimhulu Water soluble thiazolyl peptide derivatives
US20020091107A1 (en) * 2000-09-08 2002-07-11 Madar David J. Oxazolidinone antibacterial agents
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
KR20030082990A (ko) * 2001-03-15 2003-10-23 아스트라제네카 아베 메탈로프로테이나제 억제제
CA2447475A1 (en) * 2001-05-25 2002-12-05 Chu-Biao Xue Hydantion derivatives as inhibitors of matrix metalloproteinases
GB0114004D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
SE0103710D0 (sv) * 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
SE0202539D0 (sv) * 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
TWI220073B (en) * 2003-07-24 2004-08-01 Au Optronics Corp Method for manufacturing polysilicon film
US7648992B2 (en) * 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
SE0401763D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Compounds
SE0403086D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
WO2002074752A8 (en) 2004-04-22
IS6945A (is) 2003-09-10
RU2293730C2 (ru) 2007-02-20
BR0207985A (pt) 2004-06-15
EE200300450A (et) 2003-12-15
MXPA03008187A (es) 2004-01-29
CN1509273A (zh) 2004-06-30
ZA200306738B (en) 2004-11-29
US20040110809A1 (en) 2004-06-10
PL365107A1 (en) 2004-12-27
IL157650A0 (en) 2004-03-28
EE200300452A (et) 2004-02-16
PL364705A1 (en) 2004-12-13
ZA200306733B (en) 2004-11-29
NO20034027L (no) 2003-11-05
NO20034032D0 (no) 2003-09-11
NO326088B1 (no) 2008-09-15
HUP0400193A2 (hu) 2004-07-28
IL157658A0 (en) 2004-03-28
CA2444526A1 (en) 2002-09-26
UA77169C2 (en) 2006-11-15
CZ20032498A3 (en) 2004-03-17
CN1313448C (zh) 2007-05-02
NZ528108A (en) 2005-04-29
KR20030082988A (ko) 2003-10-23
NO20034027D0 (no) 2003-09-11
RU2003127731A (ru) 2005-03-20
AR035444A1 (es) 2004-05-26
NO20034032L (no) 2003-11-10
NZ528141A (en) 2005-05-27
KR20030082985A (ko) 2003-10-23
AU2002237633B2 (en) 2007-04-05
BR0208062A (pt) 2004-03-02
HUP0400328A2 (hu) 2004-09-28
MY129188A (en) 2007-03-30
WO2002074752A1 (en) 2002-09-26
HUP0400193A3 (en) 2004-10-28
IS6948A (is) 2003-09-11
KR100865836B1 (ko) 2008-10-29
JP2004527512A (ja) 2004-09-09
JP2004523582A (ja) 2004-08-05
EP1370535A1 (en) 2003-12-17
SK10942003A3 (sk) 2004-04-06
CA2440475A1 (en) 2002-09-26
CN1509274A (zh) 2004-06-30
CZ20032501A3 (cs) 2004-02-18
US20040116486A1 (en) 2004-06-17
UA74624C2 (en) 2006-01-16
HUP0400328A3 (en) 2007-05-29
SK10912003A3 (sk) 2004-05-04
MXPA03008183A (es) 2003-12-12
RU2003127736A (ru) 2005-03-27
WO2002074749A1 (en) 2002-09-26
EP1370538A1 (en) 2003-12-17

Similar Documents

Publication Publication Date Title
SE0100903D0 (sv) Compounds
SE0100902D0 (sv) Compounds
ATE227264T1 (de) Metalloproteinase-inhibitoren
NO20041493L (no) Kjemiske forbindelser.
ATE403429T1 (de) Spiropyrazol-verbindungen
WO2004083174A3 (en) Sulfonyl-amidino containing and tetrahydropyrimidino containing compounds as factor xa inhibitors
DE60335359D1 (de) Phthalazinonderivate
SE0000540D0 (sv) New compounds
SE0103710D0 (sv) Compounds
UY28014A1 (es) Compuestos quimicos
CY1106132T1 (el) Παραγωγα πιπepιδινης ως αναστολεις καναλιου καλιου
CY1106247T1 (el) Θειοφαινο- και θειαζολοσουλφοναμιδες ως αντινεοπλαστικοι παραγοντες
DK1311499T3 (da) Bicycliske forbindelser som H3-receptorligander
DE69812634D1 (de) Metalloproteinase-inhibitoren
BR0313969A (pt) Inibidores de oxitocina
NO20021409L (no) Hastighets-kontrollerte partikler
HRP20080057T3 (en) 9,10-alpha,alpha-oh-taxane analogs and methods for production thereof
PT1419163E (pt) Imidazopiridinas triciclicas
MY128164A (en) Compounds
SV2003000981A (es) Fenil-heterociclil-eteres ref. pcs10973
ATE526323T1 (de) Die hiv-protease hemmende verbindungen
NO20015892D0 (no) Inhibitorer av metallproteinaser
BRPI0416678A (pt) pirazolpirimidinas
EA200801365A1 (ru) Замещенные 5-фенил-3,6-дигидро-2-оксо-6h-1,3,4-тиадиазины
DK1562604T3 (da) Prostaglandinforbindelser til behandling af fedme